References
- Cutting GR. Cystic fibrosis genetics: from molecular
understanding to clinical application . Nat Rev Genet.
2015;16(1):45-56.
- Pereira SV, Ribeiro JD, Ribeiro AF, Bertuzzo CS, Marson FAL.Novel, rare and common pathogenic variants in the CFTR gene
screened by high-throughput sequencing technology and predicted by in
silico tools . Sci Rep. 2019;17(9):1-16.
- Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, et
al. Recommendations for the classification of diseases as CFTR
related disorders . J Cyst Fibros. 2011;10(Suppl 2):86-102.
- Justicia JL, Sole ̵́ A, Quintana-Gallego E, Gartner S, de Gracia
J,Prados C, Ma ̵́iz L. Management of pulmonary exacerbations in
cystic fibrosis: still an unmet medical need in clinical practice .
Expert Rev Respir Med. 2015;9(2):183–94.
- Illing EA, Woodworth BA. Management of the upper airway in
cystic fibrosis . Curr Opin Pulm Med. 2014;20(6):623–31.
- Cipolli M, Castellani C, Wilcken B, Massie J, McKay K, GrucaM, et al.Pancreatic phenotype in infants with cystic fibrosis identified
by mutation screening . Arch Dis Child. 2007;92(10):842–84.
- Park HW, Nam JH, Kim JY, Namkung W, Yoon JS, Lee JS, et al.Dynamic regulation of CFTR bicarbonate permeability by Cl- and
its role in pancreatic bicarbonate secretion . Gastroenterology.
2010;139(2):620-31.
- Moran A, Pillay K, Becker D, Granados A, Hameed S, Acerini CL.ISPAD Clinical Practice Consensus Guidelines 2018: Management of
cystic fibrosis-related diabetes in children and adolescents . Pediatr
Diabetes. 2018;19(Suppl 27):64-74.
- Dupuis A, Keenan K, Ooi CY, Dorfman R, Sontag MK, Naehrlich L, et al.Prevalence of meconium ileus marks the severity of mutations of
the cystic fibrosis transmembrane conductance regulator (CFTR) gene .
Genet Med. 2016;18(4):333–40.
- Flass T, Narkewicz MR. Cirrhosis and other liver disease in
cystic fibrosis . J Cyst Fibros. 2013;12(2):116–24.
- Dayangaç D, Erdem H, Yilmaz E, Şahin A, Sohn C, Özgüç M, et al.Mutations of the CFTR gene in Turkish patients with congenital
bilateral absence of the vas deferens . Hum Reprod.
2004;19(5):1094-100.
- Costes B, Girodon E, Ghanem N, Flori E, Jardin A, Soufir JC et al.Frequent occurrence of the CFTR intron 8 (TG)n 5T allele in men
with congenital bilateral absence of the vas deferens . Eur J Hum
Genet. 1995;3(5):285–93.
- Clarke LA, Sousa L, Baretto C, Amaral MD. Changes in nasal
transcriptome of native nasal epithelium expressing F508del-CFTR and
intersecting data from comparable studies . Respir Res. 2013;14(38):1-
19.
- Clarke LA, Botelho HM, Sousa L, Falcao AO, Amaral MD.Transcriptome meta-analysis reveals common differential and
global gene expression profiles in cystic fibrosis and other
respiratory disorders and identifies CFTR regulators . Genomics.
2015;106(5):268-77.
- Wright JM, Merlo CA, Reynolds JB, Zeitlin PL, Garcia JG, Guggino WB,
et al. Respiratory epithelial gene expression in patients with
mild and severe cystic fibrosis lung disease . Am J Respir Cell Mol
Biol. 2006;35(3):327-36.
- Mekus F, Ballmann M, Bronsveld I, Bijman J, Veeze H, Tümmler B.Categories of delta F508 homozygous cystic fibrosis twin and
sibling pairs with distinct phenotypic characteristics . Twin Res.
2000;3(4):277– 93.
- Terlizzi V, Lucarelli M, Salvatore D, Angioni A, Bisogno A, Braggion
C, et al. Clinical expression of cystic fibrosis in a large
cohort of Italian siblings . BMC Pul Med. 2018;18(1):1-8.
- Kormann MSD, Dewerth A, Eichner F, Baskaran P, Hector A, Regamey N, et
al. Transcriptomic profile of cystic fibrosis patients
identifies type I interferon response and ribosomal stalk proteins as
potential modifiers of disease severity . PLoS One. 2017;12(8):1-13.
- Ogilvie V, Passmore M, Hyndman L, Jones L, Stevenson B, Wilson A, et
al. Differential global gene expression in cystic fibrosis nasal
and bronchial epithelium . Genomics. 2011;98(5):327-36.
- Cutting GR. Modifier genes in Mendelian disorders: the example
of cystic fibrosis . Ann N Y Acad Sci. 2010;1214(1):57-69.
- Monin L, Gaffen SL. IL-17 family cytokines: signaling
mechanisms, biological activities and therapeutic implications . Cold
Spring Harb Perspect Med. 2018;10(4):1-24.
- Hobbs CA, Da Tan C, Tarran R. Does epithelial sodium channel
hyperactivity contribute to cystic fibrosis lung disease? J Physiol.
2013;591(18):4377-87.
- Singh AK, Riederer B, Krabbenhöft A, Rausch B, Bonhagen J, Lehmann U,
et al. Differential roles of NHERF1, NHERF2, and PDZK1 in
regulating CFTR-mediated intestinal anion secretion in mice . J Clin
Invest. 2009;119(3):540-50.
- Ganeshan R, Di A, Nelson DJ, Quick MW, Kirk KL. The interaction
between syntaxin 1A and cystic fibrosis transmembrane conductance
regulator Cl- channels is mechanistically distinct from syntaxin 1A-
SNARE interactions . J Biol Chem. 2003;278(5):2876-85.
- Boyaka E, Di A, Chang SY, Naren AP, Tousson A, Nelson DJ, et al.CFTR chloride channels are regulated by a SNAP-23/syntaxin 1A
complex . Proc Natl Acad Sci USA. 2002;99(19):12477-82.
- Chu CY, Qiu X, Wang L, Bhattacharya S, Lofthus G, Corbett A, et al.The Healthy Infant Nasal Transcriptome: A Benchmark Study . Sci
Rep. 2016;23(6):1-10.
- Ideozu JE, Rangaraj V, Abdala-Valencia H, Zhang X, Kandpal M, Sala MA,
et al. Transcriptional consequences of impaired immune cell
responses induced by cystic fibrosis plasma characterized via dual RNA
sequencing . BMC Med Genomics. 2019;12(1):1-16.
- Tang AC, Saferali A, He G, Sandford AJ, Strug LJ, Turvey SE.Endoplasmic Reticulum Stress and Chemokine Production in Cystic
Fibrosis Airway Cells: Regulation by STAT3 Modulation . J Infect Dis.
2017;215(2):293-302.
- Scambler T, Griffiths HJ, Reyna S, Pathak S, Wong C, Holbrook J, et
al. ENaC-mediated sodium influx drives NLRP3 inflammasome-
dependent autoinflammation in cystic fibrosis . eLife. 2019;8:e49248
- McElvaney OJ, Zaslona Z, Becker-Flegler K, Palsson-McDermott EM,
Boland F, Gunaratnam C, et al. Specific Inhibition of the NLRP3
Inflammasome as an Anti-Inflammatory Strategy in Cystic Fibrosis .Am J
Respir Crit Care Med. 2019;200(11):1381-91.
- Yamagishi S, Matsui T. Role of receptor for advanced glycation
end products (RAGE) in liver disease . Eur J Med Res. 2015;20(1):1-7.
- Stonebraker JR, Ooi CY, Pace RG, Corvol H, Knowles MR, Durie PR, et
al. Features of severe liver disease with portal hypertension in
patients with cystic fibrosis . Clin Gastroenterol Hepatol. 2016;
14(8):1207-15.
- Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic Variation in
CFTR and Modifier Loci May Modulate Cystic Fibrosis Disease Severity .
J Cyst Fibros. 2020;19(Suppl 1):10-14.
- Debray D, Corvol H, Housset C. Modifier genes in cystic
fibrosis-related liver disease. Curr Opin Gastroenterol.2019;35(2):88-92.